Romidepsin: a novel histone deacetylase inhibitor for cancer (Q37893664)

24 August 2017

1 reference

title

Romidepsin: a novel histone deacetylase inhibitor for cancer (English)

1 reference

24 August 2017

Erin M Bertino

1

1 reference

24 August 2017

Gregory A Otterson

series ordinal

2

1 reference

24 August 2017

language of work or name

English

0 references

publication date

24 June 2011

1 reference

Expert Opinion on Investigational Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

20

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

1151-1158

1 reference

Anticancer activities of histone deacetylase inhibitors

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Histone acetyltransferases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Histone deacetylase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

The human histone deacetylase family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Histone deacetylase inhibitors: Potential in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Nonhistone protein acetylation as cancer therapy targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Characterisation of the novel apoptotic and therapeutic activities of the histone deacetylase inhibitor romidepsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Chemical phylogenetics of histone deacetylases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Increased MDR1 expression in normal and malignant peripheral blood mononuclear cells obtained from patients receiving depsipeptide (FR901228, FK228, NSC630176).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase I trial of depsipeptide (FR901228) in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Histone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid Leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Clinical and molecular responses in lung cancer patients receiving Romidepsin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Carboplatin and Paclitaxel in combination with either vorinostat or placebo for first-line therapy of advanced non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase 2 study of vorinostat in acute myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase 1 pharmacokinetic and pharmacodynamic study of the histone deacetylase inhibitor belinostat in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2011.594437

FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity

21 January 2018

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.47.301

Identifiers

DOI

10.1517/13543784.2011.594437

1 reference

24 August 2017

1 reference